Amgen Reminds Us of Its Biotech Bloodlines; Analyst Day Notes (AMGN)
Amgen (AMGN) is one of the founding fathers of biopharma, but after showing its age in recent years with slowing drug sales and swirling safety concerns, share valuations have fallen dramatically from the high-20’s level Amgen once commanded.
We haven’t treated this company like a biotech in a long time, but Amgen is actually trading up [...]
Global Markets, I Present to you President Obama; Now What?
Well, history has been made. Barack Obama has taken a staggering 338 electoral votes, and has won the Presidency by what, in political metrics, is an all-out landslide. Just because I’m not 100% sure I’d revealed my hand already, I will say that I fully believe we’ve elected the right man for the most important [...]
A Hungry Blind Man at the Buffet
These are the days that make investors - and economists - and analysts - try to pull their hair out. I suppose some succeed. It’s not that we can’t handle down days; our skin is impervious to them now. But a day like today is rife with contradiction, uncertainty, changing rules, and low rates of [...]
Mid-Day Update - Earnings & Cherry Picking Define the Day
With major indexes essentially flat at mid-day, there doesn’t seem to be any concerted buying of safety names, as evidenced by this screen I ran:
S&P 500 Stocks with forward P/E under 10, Current Ratio over 1.0 trading down today:
105/303 (34%)
S&P 500 stocks with same metrics that are trading up today:
115/294 (39%)
So we’re seeing a [...]




